Pelthos Therapeutics Inc. (CHRO)
Jul 2, 2025 - CHRO was delisted (reason: merged into PTHS)
13.50
0.00 (0.00%)
Inactive · Last trade price on Jul 1, 2025

Channel Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1014----
Enterprise Value
1035----
PB Ratio
-15.53-1.42----
Debt / Equity Ratio
-0.35-0.80-0.20-0.15-0.30-0.07
Quick Ratio
0.010.130.020.02--
Current Ratio
0.110.340.020.02-0.02
Return on Assets (ROA)
-326.06%-645.79%-5663.30%---
Earnings Yield
-8.96%-205.89%----
Buyback Yield / Dilution
-81.07%-336.69%-193.25%---
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q